programmed cell death protein 1

programmed cell death protein 1
Name	Programmed cell death protein 1
Uniprot	P12345
Gene	PDCD1
Location	plasma membrane
Family	immunoglobulin superfamily

programmed cell death protein 1 is an immune checkpoint receptor expressed on the surface of lymphocytes and other leukocytes that modulates adaptive immune responses. It was discovered in studies of thymocyte apoptosis and later characterized through work involving researchers at institutions such as Harvard University, Stanford University, University of Pennsylvania, Washington University in St. Louis, and University of Oxford. Clinical development of antagonists targeting this receptor involved collaborations among biotechnology firms like Bristol-Myers Squibb, Merck & Co., Roche, and regulatory agencies including the Food and Drug Administration and the European Medicines Agency.

Structure and Biochemistry

The receptor is a type I transmembrane glycoprotein composed of an extracellular immunoglobulin V-set domain, a stalk, a transmembrane helix, and an intracellular tail containing immunoreceptor tyrosine-based inhibitory motifs (ITIM and ITSM). Structural characterization used methods and facilities such as X-ray crystallography at Brookhaven National Laboratory, cryo-electron microscopy at Max Planck Institute, and nuclear magnetic resonance at National Institutes of Health centers. Comparative structural studies referenced proteins from the immunoglobulin superfamily and resolved ligand interfaces with ligands from B7 family members. Post-translational modifications include N-linked glycosylation characterized in proteomics workflows at Cold Spring Harbor Laboratory and phosphorylation mapped by mass spectrometry at Scripps Research.

Expression and Regulation

Expression is induced on activated CD4+ T cell and CD8+ T cell populations following antigen receptor engagement and cytokine signals from sources studied at institutions such as NIH Clinical Center and Johns Hopkins Hospital. Additional expression occurs on B cell subsets, natural killer cell populations, and antigen-presenting cells in tissues profiled in cohorts from Mayo Clinic and Cleveland Clinic. Transcriptional regulation involves factors characterized in studies at MIT, including influences from NFAT and FoxO1 pathways, and epigenetic modulation was reported in datasets from Broad Institute and Wellcome Sanger Institute. Microenvironmental control by cytokines such as interferon-gamma, interleukin-2, and transforming growth factor beta has been documented in translational studies at Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center.

Physiological Function and Signaling

Engagement of the receptor by its ligands triggers intracellular signaling cascades that attenuate T cell receptor-mediated activation, proliferation, and cytokine production; these pathways were delineated in mechanistic work at University of California, San Francisco and University of Cambridge. Downstream effectors include recruitment of phosphatases characterized in experiments from University of Tokyo and Karolinska Institutet, leading to modulation of PI3K–AKT and MAPK pathways reported in publications from Yale University and Columbia University. In peripheral tolerance, this receptor contributes to prevention of autoimmunity in models developed at Imperial College London and Monash University. Its role in maternal–fetal tolerance and chronic infection was investigated by groups at University of Toronto and University of Melbourne.

Role in Disease and Pathology

Dysregulated expression or signaling contributes to pathologies including chronic viral infections such as HIV and hepatitis C virus, and to tumor immune evasion in malignancies studied at MD Anderson Cancer Center and Fred Hutchinson Cancer Center. Overexpression or persistent engagement is associated with T cell exhaustion described in models of lymphocytic choriomeningitis virus infection and tumor microenvironments profiled in collaborations with Dana-Farber and Memorial Sloan Kettering. Autoimmune conditions with altered checkpoint control have been reported in cohorts from Karolinska University Hospital and Hospital Clinic de Barcelona. Genetic and somatic alterations affecting pathway components have been cataloged in consortia such as The Cancer Genome Atlas and ENCODE.

Therapeutic Targeting and Clinical Applications

Therapeutic blockade using monoclonal antibodies developed by companies including Merck & Co. (pembrolizumab), Bristol-Myers Squibb (nivolumab in partnership contexts), and Roche (atezolizumab targeting related ligands) revolutionized oncology practice with approvals by the Food and Drug Administration and European Medicines Agency. Clinical indications span melanoma, non-small cell lung cancer, renal cell carcinoma, and others, with pivotal trials conducted at centers like Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Mayo Clinic. Immune-related adverse events were characterized by multidisciplinary teams at Cleveland Clinic and management guidelines issued by panels convened at American Society of Clinical Oncology and European Society for Medical Oncology. Combination strategies pairing checkpoint blockade with targeted therapies from Novartis or radiotherapy protocols tested at Massachusetts General Hospital are ongoing in trials registered by National Cancer Institute networks.

Research Tools and Experimental Models

Experimental interrogation employs monoclonal antibodies, soluble ligand constructs, CRISPR/Cas9 gene editing developed at Broad Institute, and knockout mice generated at facilities such as Jackson Laboratory. In vitro assays use primary cells sourced from blood banks affiliated with BloodCenter of Wisconsin and standardized cell lines characterized at ATCC. High-dimensional profiling techniques include single-cell RNA-seq performed using platforms from 10x Genomics and spatial transcriptomics developed in collaborations with Stanford University. Preclinical models incorporate syngeneic tumor lines, humanized mouse systems established by groups at Harvard Medical School and organoid systems being advanced at Hubrecht Institute.

Category:Immune system